CDIO vs. VRAX, NAVB, BMRA, MEDS, SQL, PXMD, SXTP, UPC, CLVR, and QLGN
Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), Biomerica (BMRA), TRxADE HEALTH (MEDS), SeqLL (SQL), PaxMedica (PXMD), 60 Degrees Pharmaceuticals (SXTP), Universe Pharmaceuticals (UPC), Clever Leaves (CLVR), and Qualigen Therapeutics (QLGN). These companies are all part of the "medical" sector.
Cardio Diagnostics vs.
Virax Biolabs Group (NASDAQ:VRAX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Cardio Diagnostics has lower revenue, but higher earnings than Virax Biolabs Group.
Cardio Diagnostics' return on equity of 0.00% beat Virax Biolabs Group's return on equity.
0.4% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 3.5% of Cardio Diagnostics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 45.9% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Virax Biolabs Group has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of -1.93, meaning that its stock price is 293% less volatile than the S&P 500.
In the previous week, Virax Biolabs Group had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.77 beat Virax Biolabs Group's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.
Cardio Diagnostics received 1 more outperform votes than Virax Biolabs Group when rated by MarketBeat users.
Cardio Diagnostics has a consensus target price of $8.00, indicating a potential upside of 1,977.92%. Given Virax Biolabs Group's higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Virax Biolabs Group.
Summary
Virax Biolabs Group and Cardio Diagnostics tied by winning 6 of the 12 factors compared between the two stocks.
Get Cardio Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cardio Diagnostics Competitors List
Related Companies and Tools